Effect of magnetic resonance imaging characteristics on uterine fibroid treatment

Nguyen Minh Duc
Huynh Quang Huy
Department of Radiology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

Abstract: Uterine fibroids are the most common gynecological benign tumors adversely affecting the quality of life of women of a reproductive age. Magnetic resonance imaging (MRI) is efficient at localizing the site of lesions and characterizing uterine fibroids before treatment. Understanding the different characteristics of uterine fibroids on MRI is essential, because it not only enables prompt diagnosis, but also guides the development of suitable therapeutic methods. This pictorial review demonstrates the effect of MRI features on uterine fibroid treatment.

Keywords: uterine fibroids, characteristics, magnetic resonance imaging, treatments

Introduction
Uterine fibroids, known as leiomyomas, are the most common gynecological benign tumors affecting premenopausal women. The symptoms include heavy or prolonged menstrual bleeding, pelvic pain/pres sure, and reproductive effects, such as subfertility and adverse pregnancy outcomes. The lifetime prevalence of fibroids is 70–80%.1,2

Magnetic resonance imaging (MRI) is more sensitive in identifying uterine fibroids than other imaging modalities, and has a high diagnostic performance in leiomyomata imaging.3–5

Several surgical or minimally invasive therapeutic modalities are available for treating uterine fibroids, including hysterectomy, laparoscopic surgery, uterine artery embolization (UAE), and high-intensity focused ultrasound (HIFU). MRI is helpful in screening, preoperative planning, treatment guidance, monitoring, and assessment of the treatment response of uterine fibroids to these therapies.6 Therefore, in this pictorial review, we demonstrated the effect of MRI features on uterine fibroid treatment.

Imaging method
The diagnostic pelvic screening procedure was adopted, using a clinical MR system (Ingenia 1.5 Tesla; Philips Healthcare, the Netherlands) to describe uterine fibroid characteristics before treatment. MRI sequences included T2-weighted (T2W) turbo-spin echo parameters (repetition time (TR)/echo time (TE)=420/160 ms; flip angle (FA)=90°; resolution=1.5×1.5×1.5 mm; field of view (FOV)=250 mm2; 133 sagittal slices; sensitivity coding [SENSE P[FH][1.8;S(RL)]2]) and dynamic contrast-enhanced (DCE)-MRI parameters (TR/TE=10/4.5 ms; FOV=240 mm2; FA=8°, 12 dynamics=20 axial slices).
Fibroid types

Uterine fibroids are commonly described by their position in relation to the surrounding myometrium as intramural, submucosal and subserosal. Intramural fibroids primarily affect the myometrium and are the most common type; they result in the distortion of the myometrium and uterine cavity (Figure 1A). UAE, HIFU, and abdominal or laparoscopic myomectomy can be used to treat intramural fibroids. Submucosal fibroids project into the endometrial cavity, proliferating in the vicinity of the endometrium (Figure 1B), and are a major cause of abnormal uterine bleeding. Previous studies have demonstrated the effectiveness of UAE and HIFU in treating submucosal fibroids without severe impairment to the endometrium. Subserosal fibroids typically extend outside the uterine wall without distorting the uterine cavity (Figure 1C), and can be treated with laparoscopic surgery. Symptoms of typical subserosal fibroids are less severe than those of other fibroid types.

Pedunculated submucosal or subserosal fibroids develop on stalks outward from the uterine surface or into the uterine cavity (Figure 2). Pain is a common symptom, due to the pressure caused by pedunculated subserosal fibroids on the nearby structures. Pedunculated submucosal fibroids cause excessive blood loss during menstrual cycles. UAE has been adopted as a substitute minimally invasive treatment for pedunculated subserosal uterine fibroids without severe complications. HIFU was also proven as being safe and effective for pedunculated subserosal fibroids not expelled into the abdominal cavity after ablation.

Uterine fibroids can be classified according to their positions: anterior wall, fundus, posterior wall, and cervix. In HIFU treatment of uterine fibroids, tumors on the anterior wall or fundus can benefit from the heat accumulation during ablation (Figure 3A and B). The distance between uterine fibroids on the posterior wall of the retroverted uterus and the skin surface is larger than that between uterine fibroids on the anterior wall of the anteverted uterus and skin surface; this is negatively correlated to the ablation efficacy. Cervical uterine fibroids interfering with cervical dilatation during childbirth are strong candidates for vaginal myomectomy (Figure 3D).

Fibroid number

Uterine fibroids can be divided into single fibroid, multiple fibroids, and uterine leiomyomatosis. It is crucial to avoid laparoscopic myomectomies in patients who have more than five fibroids, as the procedure is excessively time-consuming. Studies have demonstrated that the mean total laparoscopic operating time in patients with ≥ 2 uterine fibroids is significantly shorter than that in patients with ≥ 5 uterine fibroids. Furthermore, patients with ≥ 5 have an increased risk of technical failure of HIFU treatment. Uterine leiomyomatosis is a specific condition, manifesting in innumerable small uterine fibroids, which cause a symmetrical enlargement of the uterus. Gonadotropin-releasing
hormone (GnRH) agonists are prescribed as internal medication to preserve the uterus. Alternatively, hysterectomies are performed as a radical treatment for this distinctive disease.4,22

**Fibroid size**

The size of uterine fibroids varies from 1 cm to several centimeters (Figure 6). Indications for myomectomy via laparoscopic surgery are rapid uterine fibroid growth, heavy abnormal uterine bleeding, severe pain in the pelvis, infertility, and a uterine fibroid diameter ≥6 cm. In laparoscopic surgery, the maximal diameter of uterine fibroids should not exceed 10 cm, to avoid blood loss and a time-consuming procedure.6,23 Furthermore, uterine leiomyomatosis with a uterus size resembling that at 12–14 weeks of pregnancy or rapid development of uterine fibroids during menopause are reasonable indications for hysterectomy.6,23,24 In evidence-based analysis, the maximal diameter of uterine fibroids indicating HIFU is 10 cm, because it requires patients to adopt the prone position for ≥3 h.17,18 Patients with uterine fibroids of >10 cm are likely to experience tumor lysis syndrome after HIFU treatment;25 however, in a previous UAE study, no significant difference existed in the overall complication rate between patients with uterine fibroids of ≥10 cm (in diameter) and those with uterine fibroids of <10 cm (Table 2).26 Nevertheless, it is worth noting that, at the 3-month follow-up after UAE treatment, patients with smaller uterine fibroids exhibited a greater volume reduction than those with larger uterine fibroids.9,27

**T2W imaging**

The correlation between the T2 signal intensity (SI) of uterine fibroids and histopathology proves that “typical uterine fibroids” composed predominantly of fibroma manifest a low and homogeneous SI, degenerative uterine fibroids manifest...
a heterogeneous and variable SI, and cellular uterine fibroids with a higher smooth muscle content relative to connective fibrous tissue manifest a high and homogeneous SI. Among these types, cellular uterine fibroids are the most challenging to be adapted to therapeutic treatment.

In a previous HIFU study, T2 SI-based classification was used as the primary MRI classification parameter for determining patient suitability by classifying fibroids into one of three types by visual inspection: type I (SI lower than or equal to that of skeletal muscles; Figure 7A), type II (SI lower than that of the myometrium but higher than that of skeletal muscles; Figure 7B), or type III (SI higher than that of the myometrium; Figure 7C). They concluded that type I uterine fibroids were suitable for HIFU treatment because of greater improvement in clinical symptoms and volume reduction post-treatment. However, type III fibroids were unsuitable for HIFU treatment because of worse outcomes.

Furthermore, in previous UAE studies, patients with high-T2 SI uterine fibroids obtained greater volume reduction during the follow-up period (Table 3). The high ratio of the T2 SI of uterine fibroids to that of skeletal muscle was a negatively effective parameter,
influencing ablation quality and efficiency. Meanwhile, this high ratio was positively correlated to the outcome of UAE.

### T1-perfusion imaging

The water produced by degeneration and vascularity inside tumors can cause high SI on T2W images (Figures 8 and 9). Strong vascularity in uterine fibroids during HIFU ablation causes insufficient thermal dose in the targeted volume due to heat dissipation.

Previous case reports suggested that high-T2 SI fibroids that exhibit delayed enhancement in DCE MRIs can be treated successfully if the hyperintensity is caused by high fluid content rather than high vascularity. This proves that T2 SI-based classification is limited in differentiating high

### MRI and uterine fibroid treatment

A new classification method was recently introduced based on comparisons of the MR T1 perfusion-based time–SI curves of fibroid tissue and the myometrium in screening MRI (Group A if the time–SI curve of fibroid tissue is lower than that of the myometrium [Figure 10] and Group B if the time–SI curve of fibroid tissue is equal to or higher than that of the myometrium [Figure 11]). The results of bivariate analysis in their study revealed a very strong correlation between T1 perfusion-based classification and immediate NPV ratio. The preliminary findings of the therapeutic efficacy at 6-months follow-up also showed that there was a significant correlation between immediate nonperfused volume (NPV) ratio and transformed symptom severe score improvement ratios and fibroid volume reduction ratios. It is stated that strong perfusion uterine fibroids were better adapted to UAE than weak perfusion uterine fibroids (Table 4).

Other medical interventions, such as GnRH agonist treatment, are used primarily as preoperative therapy for reducing SI between degeneration and vascularity. To overcome this problem, T1-perfusion imaging is a robust and supplementary technique for assessing the vascularity and perfusion of tumors.

A new classification method was recently introduced based on comparisons of the MR T1 perfusion-based time–SI curves of fibroid tissue and the myometrium in screening MRI (Group A if the time–SI curve of fibroid tissue is lower than that of the myometrium [Figure 10] and Group B if the time–SI curve of fibroid tissue is equal to or higher than that of the myometrium [Figure 11]). The results of bivariate analysis in their study revealed a very strong correlation between T1 perfusion-based classification and immediate NPV ratio. The preliminary findings of the therapeutic efficacy at 6-months follow-up also showed that there was a significant correlation between immediate nonperfused volume (NPV) ratio and transformed symptom severe score improvement ratios and fibroid volume reduction ratios. It is stated that strong perfusion uterine fibroids were better adapted to UAE than weak perfusion uterine fibroids (Table 4).

Other medical interventions, such as GnRH agonist treatment, are used primarily as preoperative therapy for reducing

---

### Table 3 T2 classification and treatment options

<table>
<thead>
<tr>
<th>T2 classification</th>
<th>UAE</th>
<th>HIFU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type I</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Type II</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Type III</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

### Figure 7 Sagittal T2-weighted MRIs show uterine fibroid (white asterisk) of (A) type I with the signal intensity of uterine fibroid equal to abdominis rectus muscle (black arrow); (B) type II with the signal intensity of uterine fibroid brighter than abdominis rectus muscle (black arrow) but darker than myometrium (white arrow); and (C) type III with the signal intensity of uterine fibroid brighter than both abdominis rectus muscle (black arrow) and myometrium (white arrow).

Abbreviation: MRIs, magnetic resonance images.

### Figure 8 Sagittal T2-weighted MRI (A) shows the uterine fibroid with hyperintense area inside the tumor (white arrow). Axial contrast enhancement T1-weighted MRI (B) shows the central non-enhanced uterine fibroid corresponding to the hyperintense area of T2W image (black arrow).

Abbreviations: MRIs, magnetic resonance images; T2W, T2-weighted.

### Figure 9 Sagittal T2-weighted MRI (A) shows the uterine fibroid with hyperintense area inside the tumor (white arrow). Axial contrast enhancement T1-weighted MRI shows (B) the full-enhanced uterine fibroid (black arrow).

Abbreviation: MRI, magnetic resonance image.
Figure 10 Classification of uterine fibroid on the basis of MR T1 perfusion-based time–SI curves of uterine fibroid and the myometrium. A semi-quantitative perfusion MRI was analyzed by drawing a ROI within the area of the uterine fibroid and the myometrium on one of the perfusion MRIs (left upper, left section). The software automatically generated maps for each perfusion parameter (right upper, right section) and semi-quantitative perfusion MRI parameters (left lower, left section). The time–SI curve of the fibroid is lower than that of the myometrium.

Abbreviations: MR, magnetic resonance; MRI, magnetic resonance image; ROI, region of interest; SI, signal intensity.

Figure 11 Classification of uterine fibroid on the basis of MR T1 perfusion-based time–SI curves of uterine fibroid and the myometrium. A semi-quantitative perfusion MRI was analyzed by drawing a ROI within the area of the uterine fibroid and the myometrium on one of the perfusion MRIs (left upper, left section). The software automatically generated maps for each perfusion parameter (right upper, right section) and semi-quantitative perfusion MRI parameters (left lower, left section). The time–SI curve of the fibroid is higher than that of the myometrium.

Abbreviations: MR, magnetic resonance; MRI, magnetic resonance image; ROI, region of interest; SI, signal intensity.
Table 4 T1 perfusion classification and treatment options

<table>
<thead>
<tr>
<th>T1 perfusion classification</th>
<th>UAE</th>
<th>HIFU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Group B</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

Abbreviations: UAE, uterine artery embolization; HIFU, high-intensity focused ultrasound.

MRI and uterine fibroid treatment

The authors report no conflicts of interest in this work.

References